

# Outcomes of MDS/MPN

Outcomes for MDS/MPNs vary from person to person. Your consultant is the best person to advise you on what they expect for you.

## Overall outcomes of MDS/MPNs

Outcomes for people with MDS/MPNs vary from person to person. They depend on many factors, such as:

- The exact type of MDS/MPN you have
- The genetic changes in your cancer cells
- Your age
- Your blood test results

**Here, we cover overall survival figures. These are averages. They cannot tell you what will happen to you.**

Overall survival figures are based on what happened to groups of people with a similar diagnosis in the past. They use data collected over many years, when people may not have received treatments that are available now.

For MDS/MPNs, outcomes vary depending on your exact diagnosis.

### **MDS/MPN with neutrophilia**

People with MDS/MPN with neutrophilia live for an average of 12 to 24 months. Some people do not live as long as this. Others live longer.

### **MDS/MPN with SF3B1 mutation and thrombocytosis**

People with MDS/MPN with *SF3B1* mutation and thrombocytosis live for an average of 69 to 79 months. Some people do not live as long as this. Others live longer.

### **MDS/MPN not otherwise specified**

People with MDS/MPN not otherwise specified live for an average of 12 to 28 months. Some people do not live as long as this. Others live longer. This category includes any type

of MDS/MPN that does not fit into other categories. This means outcomes are very variable and it is even harder to draw conclusions.

If you want to know as much as possible about your outlook, talk to your haematology team. They will be able to take into consideration everything they know about you, your MDS/MPN and the care they can offer you.

## **We are here to support you**


We are here for you if you are struggling to come to terms with your diagnosis.



Call our free helpline on [08088 010 444](tel:08088010444) (Monday to Friday 9am to 4.30pm)



Send a WhatsApp message to [07500 068 065](https://www.whatsapp.com/message/07500068065) (Monday to Friday, 9am to 4.30pm)



Visit our [support page](#)



Email [support@leukaemiacare.org.uk](mailto:support@leukaemiacare.org.uk)

---

#### Sources we used to develop this information

Board PA. Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®). InPDQ Cancer Information Summaries [Internet] 2003 Sep 24. National Cancer Institute (US). Available at: <https://www.cancer.gov/types/myeloproliferative/hp/mds-mpd-treatment-pdq> [Accessed September 2025]

Breccia M. Atypical CML: diagnosis and treatment. *Hematology*. 2023 Dec 8;2023(1):476-82.

Castellino A, Santambrogio E, Rapezzi D, Massaia M. Atypical chronic myeloid leukemia: new developments from molecular diagnosis to treatment. *Medicina*. 2021 Oct 14;57(10):1104.

Cross NC, Godfrey AL, Cargo C, Garg M, Mead AJ, A British Society for Haematology Good Practice Paper. The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders. *British Journal of Haematology*. 2021 Nov;195(3):338-51.

Fontana D, Elli EM, Pagni F, Piazza R. Myelodysplastic syndromes/myeloproliferative overlap neoplasms and differential diagnosis in the WHO and ICC 2022 era: a focused review. *Cancers*. 2023 Jun 13;15(12):3175.

<https://lcdemo-stage.gb.aldryn.io/about-leukaemia/types/myelodysplasticmyeloproliferative-neoplasms-mdsmpns/outcomes-of-mdsmpn/>

Leukaemia Care Registered Charity Number 1183890. Scotland Registered Charity Number SC049802

Helpline: [08088 010 444](tel:08088010444)

Gerke MB, Christodoulou I, Karantanos T. Definitions, biology, and current therapeutic landscape of myelodysplastic/myeloproliferative neoplasms. *Cancers*. 2023 Jul 27;15(15):3815.

Haematological Malignancy Research Network (HMRN) - Incidence statistics. Available at: <https://hmrn.org/statistics/incidence>. [Accessed September 2025]

Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JK, Chen W. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. *leukemia*. 2022 Jul;36(7):1703-19.

Kuykendall AT, Tokumori FC, Komrokji RS. Traipsing through Muddy Waters: a critical review of the myelodysplastic Syndrome/Myeloproliferative neoplasm (MDS/MPN) overlap syndromes. *Hematology/Oncology Clinics*. 2021 Apr 1;35(2):337-52.

Li F, Qin T, Li B, Qu S, Pan L, Zhang P, Sun Q, Cai W, Gao Q, Jiao M, Li J. Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis. *Leukemia*. 2024 Jun;38(6):1334-41.

Mangaonkar AA, Lasho TL, Ketterling RP, Reichard KK, Gangat N, Al-Kali A, Begna KH, Pardanani A, Al Ali NH, Talati C, Sallman D. Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. *Blood cancer journal*. 2022 Feb 1;12(2):26.

Nathan DI, Feld J, El Jamal SM, Mascarenhas J, Tremblay D. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future. *Leukemia Research*. 2022 Apr 1;115:106820.

NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic syndromes. Version 2.2025. Available at: <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1446> [Accessed September 2025]

Onida F, Chalandon Y. Myelodysplastic/myeloproliferative neoplasms. *The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies*. 2024 Apr 11:685-94.

Patnaik MM, Lasho T. Evidence-Based Minireview: Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review. *American Society of Hematology Education Program Book*. 2020 Dec 4;2020(1):460-4.

Patnaik MM, Lasho TL. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. American Society of Hematology Education Program Book. 2020 Dec 4;2020(1):450-9.

Patnaik MM, Tefferi A. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management. American journal of hematology. 2023 Apr;98(4):681-9.

Patnaik MM, Tefferi A. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T)–“2021 update on diagnosis, risk-stratification, and management”. American journal of hematology. 2021 Mar;96(3):379-94.

Prieto-Torres L, Requena L, Rodriguez-Pinilla SM. Clinical, histopathological and molecular spectrum of cutaneous lesions in myelodysplastic syndrome and myeloproliferative neoplasms (MDS/MPN): an integrative review. Cancers. 2023 Dec 18;15(24):5888.

Szuber N, Orazi A, Tefferi A. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management. American journal of hematology. 2024 Jul;99(7):1360-87.

Tremblay D, Hasserjian RP, Rampal RK. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a practical guide to diagnosis and management. Leukemia. 2025 Apr 19:1-4.

---

Page last reviewed: 31 December 2025

Updated January 2026

Next review due: 31 December 2028